Tayo Sanders II is a scientist, biotech investor, and founder with extensive experience in driving innovation at the intersection of technology and biology. As an investor and board member, Tayo has been instrumental in identifying and supporting groundbreaking ventures at the forefront of drug discovery and phenotypic screening, CRISPR-based therapeutic development, and multi-omic diagnostic platforms. While at Anzu Partners, a deep tech venture capital firm in Boston, MA, he led due diligence on over 15 companies, totaling more than $130M in deployed capital. Tayo pursued his Ph.D. in Engineering Science from the University of Oxford as a Rhodes Scholar.